Map Pharmaceuticals, Inc. (MAPP) Cash Flow Statement

Click line-items for a historical chart and %

Net income (loss)	-43.76M
Depreciation and amortization	1.38M
Accretion of investment discounts, net	0
Accretion of debt payment premium	0
Stock-based compensation	6.29M
Loss on disposal of equipment and other non-cash items	177K
Accounts receivable	188K
Prepaid expenses and other current assets	184K
Other assets	0
Accounts payable	-1.88M
Accrued liabilities	233K
Deferred revenue	-2.78M
Other liabilities	-55K
Net cash provided by (used in) operating activities	-40.03M
Purchase of intangible assets and in-process research and development	0
Purchase of property and equipment	-1.83M
Purchase of short-term investments	0
Sales and maturities of short-term investments	0
Purchase of restricted investment	0
Net cash used in investing activities	-1.83M
Proceeds from issuance of convertible notes payable	0
Proceeds from issuance of debt	0
Proceeds from sales of shares through equity plans	1.13M
Repayment of debt	0
Proceeds from issuance of common stock resulting from drawdown of equity line of credit, net of issuance costs	0
Proceeds from issuance of common stock in equity offerings, net of issuance costs	56.13M
Proceeds from issuance of convertible preferred stock, net of issuance costs	0
Net cash provided by (used in) financing activities	57.26M
Net increase (decrease) in cash and cash equivalents	15.4M
Cash and cash equivalents at beginning of period	98.82M
Cash and cash equivalents at end of period	114.22M
Purchase of property and equipment through accounts payable

This is a StreetInsider.com Premium Only Page